Nark Ted C 4

What Happened
Ted C. Nark, a director of Amneal Pharmaceuticals (AMRX), had 34,819 restricted stock units (RSUs) vest in early May 2026. The filing shows a conversion/exercise of 34,819 derivative units (code M) and an award/acquisition of 19,824 shares (code A) reported at $0.00. The numbers indicate 19,824 shares were delivered to Nark and the difference (14,995 shares) was withheld/surrendered to satisfy taxes or similar obligations; no cash purchase or sale occurred.

Key Details

• Transaction dates: RSU grant noted as May 6, 2026 (award reported) and conversion/vesting activity reported May 7, 2026; Form 4 filed May 8, 2026.
• Transaction types/codes: A = award/acquisition of 19,824 shares; M = conversion/exercise of 34,819 RSUs (derivative). Prices reported $0.00 (no cash exchanged).
• Net shares: 19,824 shares issued to the insider; 34,819 RSUs vested in total, implying 14,995 shares were withheld/surrendered.
• Footnotes: F1—each RSU converts to one share; F2—these 34,819 RSUs were originally granted on May 6, 2025 and vested May 7, 2026; F3—vesting conditions described in filing.
• Timeliness: Form 4 was filed on May 8, 2026 for transactions on May 6–7, 2026 (appears timely under Section 16 two-business-day rule).
• Shares owned after the transactions were not stated in the excerpt provided.

Context
This was a routine equity award/vesting event rather than an open-market buy or sale. Code M (exercise/conversion) here denotes the RSUs converting into shares; the withheld/surrendered shares are commonly used to cover tax withholding or other obligations on vesting. Such award-related filings reflect compensation vesting and do not by themselves indicate the insider is buying or selling for investment purposes.